Evidence map›Paper›PMID 41737549›Full record

ReviewFrontiers in pharmacology2026

Pharmacogenomics of risperidone in autism spectrum disorder: a minireview.

Caroline Rafaelli de Lima Honório, Beatriz Gafanhão Bobadilha, Melina Pinheiro Conscetta, Felipe De Mello Silveira, Francisco Durigon, Aline Cristiane Planello

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Caroline Rafaelli de Lima HonórioDepartment of Morphology and Basic Pathology - Medical School, Faculdade de Medicina de Jundiaí, Jundiaí, Brazil.
Beatriz Gafanhão BobadilhaDepartment of Morphology and Basic Pathology - Medical School, Faculdade de Medicina de Jundiaí, Jundiaí, Brazil.
Melina Pinheiro ConscettaDepartment of Morphology and Basic Pathology - Medical School, Faculdade de Medicina de Jundiaí, Jundiaí, Brazil.
Felipe De Mello SilveiraDepartment of Morphology and Basic Pathology - Medical School, Faculdade de Medicina de Jundiaí, Jundiaí, Brazil.
Francisco DurigonDepartment of Morphology and Basic Pathology - Medical School, Faculdade de Medicina de Jundiaí, Jundiaí, Brazil.
Aline Cristiane PlanelloDepartment of Morphology and Basic Pathology - Medical School, Faculdade de Medicina de Jundiaí, Jundiaí, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Risperidone is one of the most widely prescribed antipsychotics for the management of irritability and associated behavioral symptoms in autism spectrum disorder (ASD), yet clinical response and adverse-effect risk vary widely among individuals. Pharmacogenomic (PGx) research has sought to explain this variability, with accumulating evidence pointing to contributions from metabolic, transporter, and neurotransmitter pathways. In this narrative minireview, we synthesize current findings on PGx factors influencing risperidone outcomes in children and adolescents with ASD.

Indexed as

autism spectrum disorderCYP2D6personalized medicinepharmacogenomicsrisperidone

Identifiers

PMID41737549
PMCPMC12926439

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.